Dynavax Technologies Current Ratio 2010-2022 | DVAX
Dynavax Technologies current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Dynavax Technologies Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.93B |
$0.24B |
3.82 |
| 2022-06-30 |
$0.96B |
$0.35B |
2.77 |
| 2022-03-31 |
$0.94B |
$0.47B |
2.02 |
| 2021-12-31 |
$0.97B |
$0.56B |
1.75 |
| 2021-09-30 |
$0.85B |
$0.53B |
1.61 |
| 2021-06-30 |
$0.58B |
$0.21B |
2.85 |
| 2021-03-31 |
$0.43B |
$0.11B |
3.91 |
| 2020-12-31 |
$0.29B |
$0.08B |
3.75 |
| 2020-09-30 |
$0.29B |
$0.07B |
4.35 |
| 2020-06-30 |
$0.27B |
$0.05B |
4.99 |
| 2020-03-31 |
$0.19B |
$0.03B |
6.63 |
| 2019-12-31 |
$0.21B |
$0.05B |
3.93 |
| 2019-09-30 |
$0.23B |
$0.05B |
4.94 |
| 2019-06-30 |
$0.19B |
$0.05B |
4.30 |
| 2019-03-31 |
$0.22B |
$0.04B |
5.27 |
| 2018-12-31 |
$0.17B |
$0.04B |
4.59 |
| 2018-09-30 |
$0.20B |
$0.03B |
6.29 |
| 2018-06-30 |
$0.23B |
$0.03B |
8.87 |
| 2018-03-31 |
$0.26B |
$0.02B |
10.85 |
| 2017-12-31 |
$0.20B |
$0.02B |
10.65 |
| 2017-09-30 |
$0.20B |
$0.01B |
15.29 |
| 2017-06-30 |
$0.13B |
$0.01B |
11.92 |
| 2017-03-31 |
$0.09B |
$0.01B |
7.24 |
| 2016-12-31 |
$0.09B |
$0.02B |
4.47 |
| 2016-09-30 |
$0.12B |
$0.03B |
3.86 |
| 2016-06-30 |
$0.15B |
$0.03B |
5.21 |
| 2016-03-31 |
$0.17B |
$0.03B |
6.97 |
| 2015-12-31 |
$0.20B |
$0.03B |
6.95 |
| 2015-09-30 |
$0.22B |
$0.02B |
11.37 |
| 2015-06-30 |
$0.10B |
$0.02B |
4.46 |
| 2015-03-31 |
$0.10B |
$0.02B |
4.98 |
| 2014-12-31 |
$0.13B |
$0.02B |
6.28 |
| 2014-09-30 |
$0.14B |
$0.02B |
5.91 |
| 2014-06-30 |
$0.16B |
$0.02B |
7.96 |
| 2014-03-31 |
$0.18B |
$0.02B |
11.37 |
| 2013-12-31 |
$0.19B |
$0.02B |
11.88 |
| 2013-09-30 |
$0.08B |
$0.02B |
5.13 |
| 2013-06-30 |
$0.09B |
$0.02B |
6.20 |
| 2013-03-31 |
$0.11B |
$0.02B |
6.34 |
| 2012-12-31 |
$0.13B |
$0.02B |
6.74 |
| 2012-09-30 |
$0.15B |
$0.03B |
5.26 |
| 2012-06-30 |
$0.17B |
$0.03B |
6.56 |
| 2012-03-31 |
$0.11B |
$0.03B |
4.27 |
| 2011-12-31 |
$0.13B |
$0.03B |
4.58 |
| 2011-09-30 |
$0.06B |
$0.01B |
5.51 |
| 2011-06-30 |
$0.07B |
$0.01B |
6.29 |
| 2011-03-31 |
$0.06B |
$0.01B |
4.87 |
| 2010-12-31 |
$0.08B |
$0.01B |
5.35 |
| 2010-09-30 |
$0.05B |
$0.02B |
2.39 |
| 2010-06-30 |
$0.06B |
$0.03B |
2.07 |
| 2010-03-31 |
$0.03B |
$0.02B |
2.00 |
| 2009-12-31 |
$0.04B |
$0.01B |
2.64 |
| 2009-09-30 |
$0.05B |
$0.01B |
4.28 |
| 2009-06-30 |
$0.06B |
$0.01B |
4.88 |
| 2009-03-31 |
$0.07B |
$0.02B |
2.70 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.503B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
